AIM ImmunoTech Appoints David Chemerow to Board and Adopts Amended Bylaws

AIM ImmunoTech Inc. announced on February 26, 2025, that its Board of Directors has unanimously appointed David I. Chemerow as an Independent Director, effective February 24, 2025. Mr. Chemerow will serve on the Board until the Company’s 2025 Annual Meeting of Stockholders.

Mr. Chemerow brings more than 40 years of experience in finance, accounting, and operations leadership. During his distinguished career, he has held senior roles at noted organizations including Comscore, Inc. and Rentrak Corporation. His previous positions include Chief Financial Officer, Treasurer, and Chief Revenue Officer, where he was instrumental during the merger of Rentrak with Comscore. In addition to his extensive corporate experience, Mr. Chemerow currently serves on multiple boards and advisory committees, broadening his expertise in both the for-profit and non-profit sectors.

The Company’s Board has confirmed that Mr. Chemerow meets the independence standards set forth under Item 407(a) of Regulation S-K. He does not have any financial or relational conflicts that could materially affect his role as a director. Compensation for his services will be consistent with that of his fellow Board members, including any committee roles he may assume.

In a related filing item, AIM ImmunoTech also announced the adoption of its Restated and Amended Bylaws. The amendment includes a revision to Section 1.6, reducing the quorum requirement for stockholder meetings from 40% to 33?%. This change is expected to streamline governance logistics at future stockholder meetings.

AIM ImmunoTech continues to advance its mission in the immuno-pharma sector by evolving its leadership and corporate governance structures. The company remains focused on the development of Ampligen® (rintatolimod), its lead investigational drug aimed at addressing multiple high-impact indications in oncology, viral diseases, and immune disorders.

Forward-looking statements in the filing caution investors to consider inherent risks and uncertainties. The Company emphasized that its current revisions and appointments are subject to the conditions and risks outlined in its recent SEC filings.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Hemispherx BioPharma’s 8K filing here.

Hemispherx BioPharma Company Profile

Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).